Chatelut Etienne, Delord Jean-Pierre, Canal Pierre
Université Paul-Sabatier, Institut Claudius-Regaud, Toulouse, France.
Invest New Drugs. 2003 May;21(2):141-8. doi: 10.1023/a:1023565227808.
Toxicity is a major concern for anticancer drugs. These compounds present a narrow therapeutic index, with a small difference between the dose required for an antitumor effect and that responsible for unacceptable toxicity. Their recommended doses are determined according to the toxicity endpoint. Moreover, toxicity is observed earlier than the therapeutic effect, so, toxic effects represent a major endpoint for pharmacodynamic studies of cytotoxic drugs. Knowledge of toxicity patterns and main factors of toxicity of anticancer drugs is required before modeling data of these studies. Hematological toxicities represent the main toxicity of the cytotoxic. However, non-hematological toxicities have become more important than hematological toxicities as pharmacodynamic endpoints in some circumstances such as high-dose chemotherapy associated with bone marrow transplantation. This paper will describe the main toxicity of the cytotoxic drugs, and its factors of both inter- and intra-patient variability. The toxicity pattern of topotecan will be examined as an example. Knowledge of the toxicity pattern of a drug constitutes a prerequirement before modeling its pharmacodynamics.
毒性是抗癌药物的一个主要问题。这些化合物的治疗指数较窄,抗肿瘤作用所需剂量与导致不可接受毒性的剂量之间差异很小。它们的推荐剂量是根据毒性终点来确定的。此外,毒性比治疗效果更早出现,因此,毒性效应是细胞毒性药物药效学研究的一个主要终点。在对这些研究的数据进行建模之前,需要了解抗癌药物的毒性模式和主要毒性因素。血液学毒性是细胞毒性药物的主要毒性。然而,在某些情况下,如与骨髓移植相关的高剂量化疗中,非血液学毒性作为药效学终点比血液学毒性更为重要。本文将描述细胞毒性药物的主要毒性及其患者间和患者内变异性的因素。将以拓扑替康的毒性模式为例进行研究。在对药物的药效学进行建模之前,了解其毒性模式是一个先决条件。